Supplementary Figure S1 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC

Authors: Jing Zeng, Sunan Cui, Daniel S. Hippe et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p><p>Top row: Squamous cell carcinoma with high pre-treatment total lesion glycolysis (TLG) on FDG PET. Following mid-treatment response and a standard 60Gy (non-boosted) plan, the patient developed locoregional progression (LRP) within 1 year, suggesting high pre-treatment TLG confers elevated LRP risk. They also developed distant metastatic progression (DM) within 1 year, which was correlated with high residual mid-treatment TLG. Bottom row: Adenocarcinoma with relatively low pre-treatment TLG and high residual mid-treatment TLG on FDG PET. A boost plan (74–90Gy) was delivered for non-response and resulted in no LRP event, yet the patient developed distant metastatic progression (DM) within 1 year, suggesting high mid-treatment TLG confers elevated DM risk.</p></jats:p>

Keywords

high midtreatment pretreatment developed progression

Supplementary Figure S1 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC

Abstract

Keywords

Related Articles

Supplementary material to "Methodological Framework for Tsunami Risk Assessment in Port Facilities"

The Application of Interactive Digital Media Reviewed From the Cognitive Abilietes of Early Childhood Education Students Aged 4-5 Years

Data from Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors

Supplementary Table S4 from &lt;i&gt;Fusobacterium nucleatum&lt;/i&gt; Promotes Exosomal LncRNA &lt;i&gt;MANCR&lt;/i&gt; Secretion from Colorectal Cancer Cells to Induce PD-L1 Expression in Macrophages

Supplementary Figure S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial

Supplementary Table S4 from <i>Fusobacterium nucleatum</i> Promotes Exosomal LncRNA <i>MANCR</i> Secretion from Colorectal Cancer Cells to Induce PD-L1 Expression in Macrophages